NCT00309257View on ClinicalTrials.gov

Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

June 30, 2008

Study Completion Date

October 31, 2009

Conditions
Alport Syndrome
Interventions
DRUG

ACE I, ATA II and Statins

DRUG

Benazepril, Valsartan and Fluvastatin

"Patients will be given a low dose of Benazepril, 10 mg/die,that, if tolerated, will be up-titrated, after a week,to 20 mg/day.~Patients will be given Valsartan, 80 mg/die,up-titrated after a week to 160 mg/die. Fluvastatin will be started at 40 mg/die.If tolerated, will up-titrated to 80 mg/die. In case of liver, muscular or renal toxicity, fluvastatin will be back-titrated to 40 mg or withdrawn as deemed appropriate."

Trial Locations (1)

24020

Clinical Research Center for Rare Diseases, Ranica

All Listed Sponsors
lead

Mario Negri Institute for Pharmacological Research

OTHER

NCT00309257 - Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome | Biotech Hunter | Biotech Hunter